tiprankstipranks
Spyre Therapeutics’ SPY001 shows efficacy, safety in Phase 1 bowel disease trial
PremiumThe FlySpyre Therapeutics’ SPY001 shows efficacy, safety in Phase 1 bowel disease trial
9d ago
Spyre Therapeutics Advances IBD Treatment Pipeline
Premium
Company Announcements
Spyre Therapeutics Advances IBD Treatment Pipeline
14d ago
Spyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
Premium
The Fly
Spyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
14d ago
Spyre Therapeutics files to sell 46.33M shares of common stock for holders
PremiumThe FlySpyre Therapeutics files to sell 46.33M shares of common stock for holders
2M ago
Spyre Therapeutics files $500M mixed securities shelf
Premium
The Fly
Spyre Therapeutics files $500M mixed securities shelf
3M ago
Wedbush bullish on Spyre Therapeutics, initiates with an Outperform
Premium
The Fly
Wedbush bullish on Spyre Therapeutics, initiates with an Outperform
3M ago
Spyre Therapeutics initiated with an Outperform at Evercore ISI
PremiumThe FlySpyre Therapeutics initiated with an Outperform at Evercore ISI
4M ago
Spyre Therapeutics doses first patients in Phase 1 trial of bowel disease drug
Premium
The Fly
Spyre Therapeutics doses first patients in Phase 1 trial of bowel disease drug
5M ago
Spyre Therapeutics Announces Updated Share Structure
Premium
Company Announcements
Spyre Therapeutics Announces Updated Share Structure
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100